Clinical Trials Logo

Clinical Trial Summary

This project will examine the association between (cardio)vascular disease, blood supply to the brain, and cerebrovascular endothelial activation. Also, we will investigate the impact of exercise rehabilitation on brain vascularization, cerebrovascular endothelial function and blood flow control.


Clinical Trial Description

This is a randomized control trial, with randomization nested within rationally-formed groups. Three major groups will be assessed: 1) Coronary artery disease (CAD) patients, 2) Metabolic Syndrome (MetS), and 3) healthy Control (CTL) participants. Allocation into the Healthy CTL versus MeTS groups will be confirmed at the pre-study screening visit based on medical questionnaires, blood sample outcomes, and ultrasound imaging (see below). All CTL and MeTS participants will be allocated by random assignment to a six-month exercise training group, or a 6-month "wait-list" training group followed by a 6-month exercise training period. The exercise training will be in accordance with American College of Sports Medicine and Canadian Society for Exercise Physiology guidelines supporting 3 days/week in the laboratory with target heart rate-based aerobic activity (~30 minutes/day) and two days of at-home activity. Based on target heart rate, levels of exercise intensity and/or duration will be adjusted every two weeks to sustain the training stimulus. CAD patients are defined here as those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. Within the recruited CAD participants, Group 1 (CADcr) will volunteer to receive a structured cardiac rehabilitation (CR) program. Group 2 (CADuc) will receive the recommendation for cardiac rehabilitation and choose not to participate (due to various reasons including distance to cardiac rehabilitation site), yet volunteer to the testing procedures at baseline and following a six month period. While random assignment is preferred, it is not feasible in CAD patients because, in our experience, geographical constraints or other personal barriers restrict access to CR and because CR is often considered the normal standard of care (they won't volunteer to avoid CR if they want CR). Instead, a naturalistic control approach will be used whereby patients who do not participate in CR may still participate by undergoing the testing before and following a six month period of time. Use of recall surveys will establish activity patterns in the non-exercise training groups or wait periods. Both groups will receive the same in-hospital education, referral to a CR program, personal prescription (referral), encouragement and follow-up. All subjects will complete a series of tests before and following the six-month interval of exercise or time control. Exercise training and the majority of testing will occur in the Laboratory for Brain and Heart Health (Labatt Health Sciences Building, Rm 402). Protocols: Cardio-respiratory Fitness: Fitness will be determined using a self-paced six-minute walk test (6MWT) that will be administered as per American Thoracic Society (ATS) guidelines whereby a physician's presence is not required. Blood Sample: After resting quietly for up to 30 min, a fasting (>3 hours) venous blood sample will be taken from the antecubital vein for analysis of blood glucose, lipids, and insulin (LifeLabs), markers of astrocyte and vascular damage (D. Fraser), endothelial function (e.g. endothelin, P-selectin) and inflammation (e.g. hsCRP, TNFa, IL-1, IL-6, IL-10), neural function markers (e.g. epinephrine, norepinephrine), and proliferative factors (e.g. NFK-B, brain-derived neurotrophic factor (BDNF), VEGF) (K. Summers). Additional samples of 10 mL whole blood will be taken to Robarts Research Institute for analysis of genetic markers of vascular risk (e.g. Apolipoprotein E (APOE) or BDNF polymorphisms (R. Hegele)) and for monocyte inflammatory profiles using flow-cytometry (G. Dekaban). Up to 5 samples of plasma (~1 mL) will be sent to Victoria Hospital for cell culture fluid-flow analysis of polymorphonuclear cell binding (G. Cepinskas). The total volume of blood sample will not exceed 60 mL. Vascular Ultrasound: Ultrasound will be used to measure artery diameters and blood flow in the Carotid Artery, Carotid Sinus, Brachial Artery and Femoral Artery. Dilation of the brachial artery will also be measured following five minutes of forearm ischemia (flow-mediated dilation) and for four minutes following a sublingual single dose (0.4 mg) of sodium nitroglycerine (standard over-the-counter self-treatment for angina). Sympathetic Nerve Activity: Peripheral sympathetic nerve activity will be obtained from the peroneal nerve using microneurography. A 200 µm-diameter, 35 mm long tungsten microelectrode tapered to an uninsulated 1- to 5-µm tip is inserted transcutaneously into the peroneal nerve just posterior to the fibular head. A reference electrode is positioned subcutaneously 1-3 cm from the recording site. A sympathetic nerve site is confirmed by the characteristic pulse-synchronous burst pattern that does not produce skin paraesthesias and that increases in frequency during a voluntary apnea and/or a Valsalva manoeuvre but not during arousal to a loud noise. Transcranial Ultrasound: A small probe held against each of the temporal windows (just behind the eyes) with a headband will measure flow velocity within the middle and/or posterior cerebral arteries. Cerebrovascular Reactivity (Hypercapnia): Subjects will breathe a hypercapnic gas mixture of 5% CO2/21% O2/Balance N2 through a 2-way non-rebreathing valve. This gas will be inspired for up to 5 minutes in each of two repeated trials separated by at least 5 minutes of recovery. Sit-to-stand test: To test dynamic rate of recovery in cerebral blood flow during transient changes in blood pressure, brain blood flow by transcranial Doppler ultrasound, blood pressure, heart rate, and end tidal CO2 (with a mask) will be measured during ~3 min of seated rest, two minutes of standing, and then a period of seated rest. This protocol may be repeated up to three times. A gas analyzer and face mask mechanism will enable measurement of expired oxygen and carbon dioxide in each of the hypercapnia and sit-to-stand tests. Electrocardiogram: A standard electrocardiogram will be collected via small surface electrodes on the chest to determine heart rate. Ventilation Patterns: A respitrace strain gauge will be placed around the chest to record breathing patterns. Blood pressure will be measured using a small cuff place on a finger (Finometer), and confirmed with upper arm sphygmomanometry. Hemoglobin saturation will be measured by a pulse oximeter on one of the digits. 1. 6-min walk test: Using a self-paced format, participants will walk back and forth along a long hallway for six minutes while the distance covered will be recorded. Participants may rest as needed throughout the test. 2. Leg and arm muscle strength (isometric). Participants will push a single arm or leg against a resistance machine while the force is measured. Three maximal-effort 3-sec repetitions will be repeated separated by a minute or two of rest. Neuropsychology Tests: These tests will study the key functional outcomes in vascular cognitive impairment and include measures related to mood, memory and cognition. The tests are pen-and-paper, will be administered by trained personnel, and, based on published standards (Hachinski et al., 2006) will include the following: Overall Cognitive Function: Montreal Cognitive Assessment (MOCA), Trail making test, and The Stroop Word-Colour Test. The latter task takes advantage of our ability to read words more quickly and automatically than we can name colors. Executive Function (Animal Naming, Controlled Oral Word), Association (Trail Making Test); Language (Boston Naming Test 2nd Edition, short form); Visuospatial (Rey-Osterrieth Complex, Figure Copy, Complex Figure Memory); Digit Span and Digit Symbol coding from the Wechsler Adult Intelligence Scale IV (WAIS-III; with Canadian norms) Memory (Rey Auditory Verbal Learning Test; http://www.wpspublish.com/store/Search?Q=Rey%20Auditory%20Verbal%20Learning%20Test%E2%84%A2%2 0(RAVLT%E2%84%A2); NOTE: In an attempt to address the practice effect problem related to repeated trials of the same test, alternate forms of some scales may be administered in a counter-balanced manner when appropriate. (Reference: V. Hachinski et al. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards, Stroke, 2006, 37:2220-2241) Magnetic Resonance Imaging (MRI): Two separate MRI protocols will be performed by each participant. These will be completed on either the 3 Tesla or 7 Tesla imaging systems at Robarts. The series of images acquired will include: 1) T1 MPRAGE anatomical, 2) FLAIR for white matter hyperintensities, 3) MR angiography for vascular architecture, 4) black-blood angiography of middle cerebral artery at baseline and again after up to five minutes of hypercapnia. Sample Schedule of Testing: These will be performed at each of the pre and post training periods. Visit 1 - Laboratory Testing 1 (3 hours) Consent: 15 min Supine rest: 30 min Blood samples: 10 min (used partly for group allocation in the pre test) Snack: 10 min Instrumentation (including transcranial Doppler and carotid artery vascular ultrasound imaging): 60 min Cerebrovascular Reactivity to hypercapnia and sit-to-stand tasks: 45 min Visit 2 - Laboratory Testing 2 (2h) Cognitive tests: 45 min Vascular imaging: 30 min Six-min walk: 10 min Leg Muscle Strength: 10 min Visit 3 - MRI Testing (<1.5 hours total time) Baseline blood pressure: 10 min MRI Preparation: 10 min Anatomical: 10 min White Matter Hyperintensities: 10 min Angiography: 20 min MR angiography of middle cerebral artery with hypercapnia: 20 min The Interventions: Rehabilitative Exercise: The cardiac rehabilitation (CR) programs will provide the initial exercise intervention for referred CAD patients (Dr. Suskin). The CR program uses standardized, prescriptive and progressive exercise (primarily aerobic exercise) practices to improve the functional capacity of patients following a clinical cardiac intervention. The CR program in London lasts for 6 months. In general, aerobic exercise training is at an intensity of 40%-70% heart rate reserve or, a rate of perceived exercise score of 11-14 (on the 6-20 Borg scale), 3-7 d/wk, at 20-60 min/session (or multiple 10-min sessions). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02715661
Study type Interventional
Source Western University, Canada
Contact
Status Completed
Phase N/A
Start date March 2016
Completion date June 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment